Follow the Versartis, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 1 February 2016 (Attribution). Among the most active insiders: Brumm Joshua T. All data is openly available.
6
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Versartis, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Versartis, Inc. is a biopharmaceutical company focused on developing treatments for endocrine disorders. It is listed on NASDAQ under the ticker symbol VSAR.